Zobrazeno 1 - 10 of 122 pro vyhledávání: '"Brian J, Moran"'
2
Long-term outcomes of a prospective randomized trial of 131Cs/125I permanent prostate brachytherapy
Autor: Manuj Agarwal, Antony Koroulakis, C. DeCesaris, Michelle H. Braccioforte, Brian J. Moran, Neha P. Amin
Publikováno v: Brachytherapy. 20:38-43
Purpose Iodine-125 (125I) is the most commonly used isotope for prostate brachytherapy (BT). Cesium-131 (131Cs) has a higher dose rate and shorter dose delivery time resulting in decreased duration of acute urinary morbidity. Long-term data suggest e
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d76f9970e9c63d58c4d8249b99d2d100
https://doi.org/10.1016/j.brachy.2020.07.005
Zobrazit plný text záznamu
3
Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts
Autor: Amar U. Kishan, Alison Steigler, James W. Denham, Almudena Zapatero, Araceli Guerrero, David Joseph, Xavier Maldonado, Jessica K. Wong, Bradley J. Stish, Robert T. Dess, Avinash Pilar, Chandana Reddy, Trude B. Wedde, Wolfgang A. Lilleby, Ryan Fiano, Gregory S. Merrick, Richard G. Stock, D. Jeffrey Demanes, Brian J. Moran, Phuoc T. Tran, Santiago Martin, Rafael Martinez-Monge, Daniel J. Krauss, Eyad I. Abu-Isa, Thomas M. Pisansky, C. Richard Choo, Daniel Y. Song, Stephen Greco, Curtiland Deville, Todd McNutt, Theodore L. DeWeese, Ashley E. Ross, Jay P. Ciezki, Derya Tilki, R. Jeffrey Karnes, Jeffrey J. Tosoian, Nicholas G. Nickols, Prashant Bhat, David Shabsovich, Jesus E. Juarez, Tommy Jiang, T. Martin Ma, Michael Xiang, Rebecca Philipson, Albert Chang, Patrick A. Kupelian, Matthew B. Rettig, Felix Y. Feng, Alejandro Berlin, Jonathan D. Tward, Brian J. Davis, Robert E. Reiter, Michael L. Steinberg, David Elashoff, Paul C. Boutros, Eric M. Horwitz, Rahul D. Tendulkar, Daniel E. Spratt, Tahmineh Romero
Publikováno v: JAMA oncology, vol 8, iss 3
JAMA Oncology
Key Points Question What is the optimal minimum duration of androgen deprivation therapy (ADT) when treating high-risk prostate cancer with high-dose radiotherapy? Findings This patient-level cohort study of 3 cohorts found a significant interaction
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bf4397cad9de2f66c9946476bffe693
https://escholarship.org/uc/item/9m28n0vg
Zobrazit plný text záznamu
5
Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features
Autor: Eyad Abu-Isa, Albert J. Chang, Wolfgang Lilleby, Jeffrey J. Tosoian, Robert E. Reiter, Brian J. Moran, Robert T. Dess, Trude B. Wedde, Theodore L. DeWeese, D. Jeffrey Demanes, Patrick A. Kupelian, Todd McNutt, Ridwan Alam, Prashant Bhat, Tahmineh Romero, Santiago Martin, Daniel E. Spratt, Thomas M. Pisansky, Nicholas G. Nickols, Giovanni Motterle, Rafael Martínez-Monge, J.K. Wong, Gregory S. Merrick, Derya Tilki, Matthew Rettig, R. Jeffrey Karnes, Jesus E. Juarez, Michael L. Steinberg, Phuoc T. Tran, Hartwig Huland, Bradley J. Stish, Eric M. Horwitz, David Elashoff, Danny Y. Song, Bruce J. Trock, Alejandro Berlin, Chandana A. Reddy, David Shabsovich, Daniel J. Krauss, Brian J. Davis, Eric A. Klein, Michelle H. Braccioforte, Curtiland Deville, Rahul D. Tendulkar, Richard G. Stock, Natalie Chong, Paul C. Boutros, Jay P. Ciezki, Jonathan D. Tward, Ryan Fiano, Rebecca Levin-Epstein, Zeyad Schwen, Richard Choo, Ashley E. Ross, Avinash Pilar, Anthony V. D'Amico, Amar U. Kishan, Stephen Greco
Publikováno v: JAMA Network Open
Key Points Question Are external beam radiotherapy, with or without brachytherapy boost, or radical prostatectomy associated with differences in prostate cancer–specific mortality or distant metastasis outcomes in patients with high-risk prostate c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83931bffc35ba528f0951d3d49ede14a
http://europepmc.org/articles/PMC8251338
Zobrazit plný text záznamu
6
Long-term biochemical outcomes using cesium-131 in prostate brachytherapy
Autor: Neha P. Amin, Stephanie R. Rice, Arpit M. Chhabra, Manuj Agarwal, Brian J. Moran, Michelle H. Braccioforte
Publikováno v: Brachytherapy. 18:800-805
Purpose Long-term outcomes reveal equivalent biochemical outcomes with low-dose-rate (LDR) brachytherapy (BT) compared with radical prostatectomy and external-beam radiotherapy for the management of prostate cancer. Iodine-125, the most commonly used
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea52c77b6426959588d397090a61f73b
https://doi.org/10.1016/j.brachy.2019.07.002
Zobrazit plný text záznamu
7
The Relationship Between Androgen Deprivation Therapy Duration and External Beam Radiotherapy With or Without a Brachytherapy Boost in High-Risk Prostate Cancer
Autor: Eric M. Horwitz, Wolfgang Lilleby, D.J. Demanes, Trude B. Wedde, Tahmineh Romero, R. Martinez-Monge, Robert T. Dess, Phuoc T. Tran, J.K. Wong, Jonathan D. Tward, Alejandro Berlin, A.U. Kishan, B.J. Stish, Richard G. Stock, Rahul D. Tendulkar, Daniel E. Spratt, Brian J. Moran, Gregory S. Merrick, Daniel J. Krauss, Michael L. Steinberg
Publikováno v: International Journal of Radiation Oncology*Biology*Physics. 111:S76-S77
PURPOSE/OBJECTIVE(S) The use/prolongation of androgen deprivation therapy (ADT) with external beam radiotherapy (EBRT) improves distant metastasis outcomes in patients with high-risk prostate cancer. The optimal duration of ADT when adding a brachyth
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bd115c8ae4c7bc2a71f4826db6ad7829
https://doi.org/10.1016/j.ijrobp.2021.07.186
Zobrazit plný text záznamu
8
The risk of death from prostate cancer in men with Gleason score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapy
Autor: Ming-Hui Chen, Brian J. Moran, Michelle H. Braccioforte, Jing Wu, Anthony V. D'Amico, David D. Yang
Publikováno v: Urologic oncology. 40(1)
We evaluated whether intermediate-risk factors, in addition to age, were associated with risk of prostate cancer-specific mortality (PCSM) among men with Gleason 3+4 prostate cancer.We conducted a prospective cohort study of 1,920 men with Gleason 3+
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f395aeb1ceced2cc8acf1d706edb3d8
https://pubmed.ncbi.nlm.nih.gov/34315661
Zobrazit plný text záznamu
10
Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer
Autor: Jason K. Molitoris, Arpit M. Chhabra, Manuj Agarwal, Michelle H. Braccioforte, Neha P. Amin, Brian J. Moran
Publikováno v: Brachytherapy. 17:882-887
Purpose The available data demonstrating that superiority of LDR brachytherapy (LDR-BT) boost in high-risk prostate cancer patients under represents patients with extracapsular extension (T3a) and/or seminal vesicle invasion (T3b) have been limited.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f86e69b3b1f6712ed5963e9c0551c9e
https://doi.org/10.1016/j.brachy.2018.07.001
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje